From Our Partners
Sunday, July 3, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Genetic Changes in Ebola Could Impede Countermeasures

by Global Biodefense Staff
January 21, 2015
BARDA Funds Ebola ZMapp Drug

Colorized scanning electron micrograph of filamentous Ebola virus particles (green) attached and budding from a chronically infected VERO E6 cell (orange) (25,000x magnification). Image captured and color-enhanced at the NIAID Integrated Research Facility in Ft. Detrick, Maryland. Credit: NIAID

Scientists studying the genetic makeup of the Ebola virus currently circulating in West Africa have identified several mutations that could have implications for developing effective drugs to fight the virus.

Their findings, published in mBio, the online open-access journal of the American Society for Microbiology, identified changes in the current West African outbreak strain that could potentially interfere with experimental, sequence-based therapeutics.

Researchers from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), working with investigators from Harvard University and the Massachusetts Institute of Technology, have evaluated three types of genetic sequence-based treatments during the current outbreak: monoclonal antibody, small-interfering RNA (siRNA), and phosphorodiamidate morpholino oligomer (PMO) drugs.

All three countermeasures were developed using Ebola virus strains from two smaller outbreaks that occurred in 1976 and 1995.

“We wanted to highlight an area where genomic drift, the natural process of evolution on this RNA virus genome, could affect the development of therapeutic countermeasures,” says Gustavo Palacios, senior author of the study and director of the Center for Genome Sciences at USAMRIID.

The team compared the current strain, called EBOV/Mak, with the two previous strains that caused outbreaks in 1976 and 1995 in Zaire (now the Democratic Republic of the Congo). In each comparison, they found more than 600 genetic mutations.

Next, the group focused on only the mutations that occurred in the genetic sequences targeted by the experimental therapeutics. Of these, they found 10 new mutations that might interfere with the mechanisms of the sequence-based drugs currently being tested. Three of these mutations appeared during the current West African outbreak.

The researchers say genetic drift must be considered when developing potential therapeutics, in order to ensure that changes in the Ebola virus over time do not render those treatments ineffective.

“Based on our findings, the virus has changed and is continuing to change,” said CPT Jeffrey Kugelman, Ph.D., the paper’s first author. Kugelman is currently in Charlesville, Liberia at the Liberian Institute for Biomedical Research, working with the local government to set up onsite genomics sequencing of Ebola patient samples to get a real-time picture of how the virus changes as it is transmitted from human to human.

His work will be critical to analyzing changes in the virus’s genetic sequences over time and determining how those changes may affect future diagnostic tests and drug treatments.

Read the paper at mBio: Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics.

From Our Partners
Tags: AntiviralsBARDAEbolaEmerging ThreatsUSAMRIIDVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
Biosecurity

Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies

June 14, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC